Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VOR with free AI briefings, catalyst countdowns, and dilution alerts.

VOR · Vor Biopharma Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$481.6M Cash on Hand
49.7mo Cash Runway
Follow VOR by email Get an email when VOR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VOR, unsubscribe in one click. Privacy

📣 What VOR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Telitacicept Generalized Myasthenia Gravis Phase 3 · NCT06456580 Active not recruiting
Allogeneic Anti-CD33 CAR T-cells VCAR33 Leukemia, Myeloid, Acute Phase 1/2 · NCT05984199 Terminated
Tremtelectogene Empogeditemcel (VOR33) Leukemia, Myeloid, Acute Phase 1/2 · NCT04849910 Terminated

Also used in these trials (approved or third-party drugs, not VOR's own candidates): Gemtuzumab Ozogamicin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VOR holds $481.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.1M/quarter from operations, an estimated runway of 49.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VOR files for a raise →

👥 Who Owns VOR

Insiders 13.9% Other 5%+ holders 40.7% Institutions (180 holders) 45.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
ForGrowth III PA B.V. 5%+ holder (13D) 10,237,714 16.66% 2025-12-18
FMR LLC Institution (13G, 5%+) 6,318,525 10.29% 2026-09-30
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 5,676,370 9.24% 2026-06-30
Chen Yu 5%+ holder (13G) 5,673,078 9.23% 2026-03-30
RA CAPITAL MANAGEMENT, L.P.
10% owner · +7.96M options
Insider 4,503,382 7.33% 2026-10-02
Verve Capital Limited 5%+ holder (13G) 3,410,892 5.55% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 3,099,259 5.04% 2026-06-30
TCG Crossover GP II, LLC
10% owner
Insider 2,836,539 4.62% 2026-03-30
Reprogrammed Interchange LLC
10% owner
Insider 1,166,909 1.90% 2025-10-17
Peter Kolchinsky Institution (13G, 5%+) 810,671 1.32% 2025-10-28
Jeremy Brett Sokolove
Chief Medical Officer
Insider 25,983 0.04% 2026-11-02

Share count 61,434,344 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VOR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VOR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.